Skip to main content

Advertisement

SpringerLink
Log in

Role of Virus-Directed Therapy in Soft Tissue Sarcoma

  • Sarcoma (SH Okuno, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Bone and soft tissue sarcoma are rare cancers of mesenchymal origin with the characteristics of heterogeneity and diversity that account for less than 1% of solid malignant cancers. Conventional chemotherapy remains standard of care with response rates of 10–15% that are usually dependent on histologic subtype as some subtypes are chemotherapy resistant. There remains a large unmet clinical need for new and novel options promoting the development of promising therapeutic options such as immunotherapy. With more than 80 different subtypes, the heterogeneity of sarcoma requires thoughtful clinical trial design. In the sarcoma field, recent breakthroughs have occurred in the context of histology-specific approach based on underlying tumor biology. To that end, immunotherapy approaches will need to take a similar approach. Oncolytic viruses (OVs) have emerged as a promising treatment for many solid tumors and shown encouraging results in sarcoma. This review mainly focuses on collective clinical data highlighting the role of OVs as immunotherapy being used in soft tissue sarcoma (STS) and bone sarcomas. Combining OVs with T cell-activating checkpoint inhibition, adoptive cell therapy or targeted therapies may yield increased potency, improve antitumor efficacy of oncolytic virotherapy, and offer a new prospect for the treatment of sarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Macedo N, Miller DM, Haq R, et al. Clinical landscape of oncolytic virus research in 2020. Journal for ImmunoTherapy of Cancer. 2020;8:e001486.

    Article  Google Scholar 

  2. Cripe TP, Mackall CL. Exploiting genetic alterations to design novel therapies for cancer. Hematol Oncol Clin North Am. 2001;15:657–75.

    Article  CAS  Google Scholar 

  3. Birdi HK, Jirovec A, Cortés-Kaplan S, et al. Immunotherapy for sarcomas: new frontiers and unveiled opportunities. J Immunother Cancer. 2021;9(2):e001580. https://doi.org/10.1136/jitc-2020-001580.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Howells A, Marelli G, Lemoine NR, Wang Y. Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer. Front Oncol. 2017;7:195. https://doi.org/10.3389/fonc.2017.00195.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.

    Article  CAS  Google Scholar 

  6. Kelly CM, Antonescu CR, Bowler T, et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol. 2020, 6(3):402–8. https://doi.org/10.1001/jamaoncol.2019.6152 Recent phase II clinical study reporting the endpoints in advanced sarcoma with the use of T-VEC plus PD-1 inhibitor.

  7. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–501.

    Article  CAS  Google Scholar 

  8. Lazar AJ, et al. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(4):950–65.

    Article  Google Scholar 

  9. Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47:1402–7.

    Article  CAS  Google Scholar 

  10. Streby KA, et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res. 2017;23(14):3566–74.

    Article  CAS  Google Scholar 

  11. Veldwijk MR, Berlinghoff S, Laufs S, et al. Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors. Cancer Gene Ther. 2004;11(8):577–84. https://doi.org/10.1038/sj.cgt.7700718.

    Article  CAS  PubMed  Google Scholar 

  12. Opyrchal M, Aderca I, Galanis E. Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol. 2009;542:705–17.

    Article  CAS  Google Scholar 

  13. Dobner T, Horikoshi N, Rubenwolf S, Shenk T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science. 1996;272(5267):1470–3.

    Article  CAS  Google Scholar 

  14. Martinez-Velez N, Xipell E, Jauregui P, et al. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity. J Bone Miner Res. 2014;29(10):2287–96.

    Article  CAS  Google Scholar 

  15. Bone and soft-tissue sarcoma: a new target for telomerase-specific oncolytic virotherapy. Extensive review of hTERT promoter-driven oncolytic adenoviruses against bone and soft-tissue sarcoma cells with telomerase activity.

  16. Nemunaitis J, Tong AW, Nemunaitis M, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 2010;18(2):429–34. https://doi.org/10.1038/mt.2009.262.

    Article  CAS  PubMed  Google Scholar 

  17. Zhu Z, et al. Co-expression network analysis identifies four hub genes associated with prognosis in soft tissue sarcoma. Front Genet. 2019;10:37.

    Article  CAS  Google Scholar 

  18. Woo Y, et al. The oncolytic activity of myxoma virus against soft tissue sarcoma is mediated by the overexpression of ribonucleotide reductase. Clin Med Insights: Oncol. 2021;15:1179554921993069 Preclinical study showing a direct correlation between myxoma virus oncolysis and RRM2 RNA levels in STS.

  19. Le Boeuf, F, et al. Oncolytic maraba virus MG1 as a treatment for sarcoma Int J Cancer 141.6 (2017): 1257-1264

  20. Monga V, Skubitz KM, Maliske S, Mott SL, Dietz H, Hirbe AC, et al. A retrospective analysis of the efficacy of immunotherapy in metastatic soft-tissue sarcomas. Cancers. 2020.

  21. Katz D, Palmerini E, and Pollack SM. More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments Am Soc Clin Oncol Educ Book 38 (2018): 925-938.

  22. Zamarin D, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128(4):1413–28.

    Article  Google Scholar 

  23. Fridlender ZG, et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther. 2010;18(11):1947–59.

    Article  CAS  Google Scholar 

  24. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol. 2008;20(2):241–6.

    Article  CAS  Google Scholar 

  25. Raj S, Miller LD, and Pierre L. Triozzi. Addressing the adult soft tissue sarcoma microenvironment with intratumoral immunotherapy Sarcoma 2018 (2018).

  26. Hamacher R, and Bauer S. Preclinical models for translational sarcoma research Curr Opin Oncol 29.4 (2017): 275-285.

  27. Penn I. "Sarcomas in organ allograft recipients." Transplantation 60.12 (1995): 1485-1491.

  28. Angelo SPD’, Tap WD, Schwartz GK, Carvajal RD, "Sarcoma immunotherapy: past approaches and future directions", Sarcoma, vol. 2014, Article ID 391967, 13 pages, 2014. A review focusing on innovative future directions in sarcoma that could help design combinational therapeutic study designs with OVs.

  29. Pollack SM, Ingham M, Spraker MB, Schwartz GK. Emerging targeted and immune-based therapies in sarcoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36(2):125–35.

    Article  CAS  Google Scholar 

  30. Lettieri CK, Hingorani P, Kolb EA. Progress of oncolytic viruses in sarcomas. Expert Rev Anticancer Ther. 2012;12(2):229–42.

    Article  CAS  Google Scholar 

  31. Sharma, Anu, et al. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature Clin Cancer Res 19.17 (2013): 4843-4853

  32. Boxberg M, Steiger K, Lenze U, Rechl H, von Eisenhart-Rothe R, Wörtler K, et al. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue-prognostic implications and rationale for immunotherapy. Oncoimmunology. 2017;7(3):e1389366.

    Article  Google Scholar 

  33. D’Angelo SP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357–65.

    Article  Google Scholar 

  34. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Sarcoma, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering, 1275 York Ave, New York, NY, 10065, USA

    Hira Chaudhary & Sandra D’Angelo

Authors
  1. Hira Chaudhary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra D’Angelo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandra D’Angelo.

Ethics declarations

Conflict of interest

Hira Chaudhary and Sandra D’Angelo each declare no potential conflicts of interest.

Human and animal rights and informed consent

The article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Sarcoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chaudhary, H., D’Angelo, S. Role of Virus-Directed Therapy in Soft Tissue Sarcoma. Curr. Treat. Options in Oncol. 23, 404–414 (2022). https://doi.org/10.1007/s11864-022-00956-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-022-00956-2

Keywords

Search

Navigation